Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > News out 👀

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Oct 26, 2022 3:42pm

75 Views

Post# 35051077

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:News out 👀

It's challenging in cancer because of the seamless, ever expanding nature of the trials. I was looking at Trodelvy/Erhurtu timeline and one of them doesn't even list separate Ph1/Ph2 trials. They both are part of the same clinicaltrials.gov trial number. I'd put aside just a simple look at the phase number and ask how many patients getting enrolled? What's the aim of this trial? And how that matches with THTX's aims atm. I think that's the only way to do it given the greater flexibility in cancer with the fda.

PWIB123 wrote: Appreciate the references qwerty22. So, while timelines weren't met initially and the trial has seemed slow, maybe THTX is not that far out of line with what is normal. Someone earlier mentioned that we are 20 months into the Ph.1. I wasn't sure if Ph.1 a is considered a separate timeline from Ph.1b, when considering a 3 month to 1 year timeframe for completion, or if they are combined. I assumed they are two separate timelines.

qwerty22 wrote: Bicycle started their lead Ph1 with BT5528 in Nov 2019.
https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-first-patient-dosed-phase-iii

It took them until Oct 2021 to give a readout on the first 24 patients.
https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-interim-bt5528-phase-i-clinical

By Sept 2022 they were still only reading out on 29 patients.
https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-bt5528-phase-i-dose-escalation

IDK if Bicycle and Sutro are just as slow as THTX but they all look to be on similar timelines. Looks to me like some of Bicycle's important readouts happened 2-3 years after the start of Ph 1.